Abstract
It is well established that Helicobacter pylori infection is a primary cause of gastritis. There is an alarming potential for this infection to progress into gastric cancer if left unaddressed. However, the efficacy of conventional treatments is undermined by the growing challenge of antibiotic resistance and the necessity for complex multidrug and high-dose therapeutic regimens. Furthermore, the presence of factors such as biofilm formation, efflux pumps, and gene mutations significantly elevates the risk of treatment failure. In view of these significant challenges, contemporary drug delivery systems represent a vital adjunct in the battle against H. pylori. These advanced and sophisticated systems offer significant advantages, including enhanced drug protection, controlled release, and targeted delivery to specific tissues. Nanoparticles, in particular, show promise in combating H. pylori infection through a variety of mechanisms, including direct drug delivery into the bacteria and the destruction of bacterial walls, as well as generation of free radicals. This review provides an overview of the current therapeutic landscape, including both existing and evolving treatment options. It delves into the transformative potential of novel drug delivery systems, including micro- and nanoparticles, to play a transformative role in the complex field of H. pylori infection treatment. By examining the complex relationship between infection dynamics and cutting-edge delivery technologies, this review seeks to identify avenues for more effective and targeted interventions against this persistent threat. As our understanding of H. pylori infection advances, new treatments and enhanced drug delivery methods offer the prospect of a more effective and personalized approach to combating this persistent health problem. This dynamic intersection of microbiology and nanotechnology exemplifies the relentless pursuit of innovative solutions to safeguard against the formidable challenges posed by H. pylori. Ultimately, it offers hope for improved patient outcomes and a healthier population.